BridgeBio: Optionality From Rare-Disease Revenues to a KRAS Play
BridgeBio (BBIO) is staging a transition from a pure rare-disease developer to a commercial-stage company with optionality for oncology expansion. Recent wins (Attruby long-term mortality data, positive BBP-418 Phase 3 readout, achondroplasia data) should drive revenue and M&A firepower that could be redeployed into KRAS-targeted assets or partners…